Squarepoint’s Hemab Therapeutics COAG Stock Holding History

Squarepoint’s Portfolio COAG Stock Details COAG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	–	Sell	-6,252	Closed	-$230K	–	5191
2026 Q2	$230K	Buy	+6,252	New	+$173K	﹤0.01%	3979

Other funds holding COAG

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return

Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13B AUM 35.88% 1-Year Est. Return

Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return

Squarepoint's COAG Position: Q3 2026 in Review

Squarepoint sold out of Hemab Therapeutics (COAG) in Q3 2026, closing a stake of 6,252 shares — an estimated $230K sold.

Squarepoint first reported a position in COAG in Q2 2026 and held it in 1 quarter. The position peaked at $230K in Q2 2026. 13 funds tracked by Wall St. Rank hold COAG as of Q3 2026.

Squarepoint reported no remaining Hemab Therapeutics position as of Q3 2026 after selling out during the quarter.
Squarepoint sold 6,252 Hemab Therapeutics shares in Q3 2026, an estimated $230K.
Squarepoint first reported a position in Hemab Therapeutics in Q2 2026 and held it in 1 quarter.
Squarepoint's Hemab Therapeutics position peaked at $230K in Q2 2026.
13 funds tracked by Wall St. Rank held Hemab Therapeutics as of Q3 2026.

Based on Squarepoint's 13F filing for Q3 2026, filed 9 Nov 2026.